Global Atopic Dermatitis Epidemiology and Patient-Based Market 2015-2024: Dupilumab is Expected to be the First Biologic Approved for Atopic Dermatitis

DUBLIN, August 12, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Atopic Dermatitis: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

Dupilumab is expected to be the first biologic approved for atopic dermatitis, offering a novel treatment option for the most severe patients and driving a strong CAGR of 15.6% during the 2015-24 forecast period.

This report addresses the following questions:

- Where is the untapped commercial opportunity in the atopic dermatitis market?
- How will the late-phase candidates dupilumab and crisaborole fit into the existing atopic dermatitis treatment algorithm?
- What do surveyed dermatologists consider to be the greatest unmet needs in atopic dermatitis?
- What role does pricing and reimbursement play in prescribing for atopic dermatitis and what impact will the launch of new therapies have on this?
- How do prescribing patterns change as disease severity increases?

Key Topics Covered:

FORECAST: ATOPIC DERMATITIS

- Market Overview and Trends
- Market Definition and Methodology
- crisaborole
- dupilumab
- Elidel (pimecrolimus)
- Elocon (mometasone furoate)
- Protopic (tacrolimus)
- Primary Research Methodology

TREATMENT: ATOPIC DERMATITIS

- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Persistence and Compliance
- Unmet Needs in Atopic Dermatitis
- Prescribing Influences
- Pipeline Drugs and Future Treatment

EPIDEMIOLOGY: ATOPIC DERMATITIS

- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: ATOPIC DERMATITIS

- Product profile: Elidel
- Product profile: Elocon
- Product profile: Medrol
- Product profile: Protopic
- Product profile: Toctino

PIPELINE: ATOPIC DERMATITIS

- Product profile (late stage): crisaborole
- Product profile (late stage): dupilumab

For more information about this report visit http://www.researchandmarkets.com/research/342k5h/atopic

Related Topics: Immune Disorders Drugs, Dermatological Drugs

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com